Patrizia Della Valle
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Patrizia Della Valle has a total of 217 co-authors. Here are the top co-authors by number of shared publications:
- Armando D'Angelo
Coagulation Service & Thrombosis Research Unit, San Raffaele Scientific Institute, Milan, Italy
32 shared publications - Matteo Pecchiari
Department of Pathophysiology and Transplantation, Università degli Studi di Milano, 20122 Milano, Italy
5 shared publications - Alberto Zangrillo
Department of Anesthesia and Intensive Care, IRCCS San Raffaele Scientific Institute, Milan, Italy
4 shared publications - Alessio Cantore
San Raffaele Telethon Institute for Gene Therapy, IRCCS San Raffaele Scientific Institute
4 shared publications - Guendalina Gentile
University of Milan, Department of Biomedical Sciences for Health, Laboratory of Forensic Histopathology and Microbiology - Section of Forensic and Insurance Medicine, Milan, Italy
4 shared publications - Loris Pozzi
Coagulation Service and Thrombosis Research Unit, San Raffaele Scientific Institute
4 shared publications
Latest Publications
- Open Access
- 28 August 2026
- Published by PAGEPress Publications in Bleeding, Thrombosis and Vascular Biology
- Vol. 5 (3) , 1-8
Whole exome sequencing in a family with thromboangiitis obliterans
Low-frequency candidates for susceptibility to thromboangiitis obliterans (TAO) were investigated by whole exome sequencing in a family with a young member with migrating thrombophlebitis, artery thrombosis, and ulcerations followed by below-knee amputation. Filtering among 193 candidates for venous thromboembolism (VTE) detected rare heterozygous variants: the PPIF (peptidylprolyl-isomerase F) frameshift p.Tyr121fs*0 [minor allele frequency (MAF)= 0.000004], the F2 (thrombin) synonymous/splicing p.Gly271=, and 5 missense variants. Among these, the novel PTGIR (prostaglandin I2 receptor) p.Tyr144Asn would interfere with transmembrane helix interaction, and potentially decrease prostacyclin response. Filtering among 92 genes, suggested by previous genomic and transcriptomic studies in TAO patients, detected a rare combination of HLA-DQB1 alleles, and two in linkage variants (MAF=0.0003) in titin (TTN). Interestingly, TTN is also reported among VTE proteome alterations. By exploring the whole exome, the novel BET1 nonsense p.Glu33Ter change may indirectly influence hemostasis and endothelial integrity. This study pinpoints novel TAO candidate genetic components for further investigation
- 28 August 2026
- Published by PAGEPress Publications in Bleeding, Thrombosis and Vascular Biology
- Vol. 5 (3) , 1-8
Open AccessWhole exome sequencing in a family with thromboangiitis obliterans
Low-frequency candidates for susceptibility to thromboangiitis obliterans (TAO) were investigated by whole exome sequencing in a family with a young member with migrating thrombophlebitis, artery thrombosis, and ulcerations followed by below-knee amputation. Filtering among 193 candidates for venous thromboembolism (VTE) detected rare heterozygous variants: the PPIF (peptidylprolyl-isomerase F) frameshift p.Tyr121fs*0 [minor allele frequency (MAF)= 0.000004], the F2 (thrombin) synonymous/splicing p.Gly271=, and 5 missense variants. Among these, the novel PTGIR (prostaglandin I2 receptor) p.Tyr144Asn would interfere with transmembrane helix interaction, and potentially decrease prostacyclin response. Filtering among 92 genes, suggested by previous genomic and transcriptomic studies in TAO patients, detected a rare combination of HLA-DQB1 alleles, and two in linkage variants (MAF=0.0003) in titin (TTN). Interestingly, TTN is also reported among VTE proteome alterations. By exploring the whole exome, the novel BET1 nonsense p.Glu33Ter change may indirectly influence hemostasis and endothelial integrity. This study pinpoints novel TAO candidate genetic components for further investigation
- Open Access
- 7 September 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (18) , 13809
Whole-Exome Sequencing in a Family with an Unexplained Tendency for Venous Thromboembolism: Multicomponent Prediction of Low-Frequency Variant Deleteriousness and of Individual Protein Interaction
Whole-exome sequencing (WES) in families with an unexplained tendency for venous thromboembolism (VTE) may favor detection of low-frequency variants in genes with known contribution to hemostasis or associated with VTE-related phenotypes. WES analysis in six family members, three of whom affected by documented VTE, filtered for MAF < 0.04 in 192 candidate genes, revealed 22 heterozygous (16 missense and six synonymous) variants in patients. Functional prediction by multi-component bioinformatics tools, implemented by a database/literature search, including ClinVar annotation and QTL analysis, prioritized 12 missense variants, three of which (CRP Leu61Pro, F2 Asn514Lys and NQO1 Arg139Trp) were present in all patients, and the frequent functional variants FGB Arg478Lys and IL1A Ala114Ser. Combinations of prioritized variants in each patient were used to infer functional protein interactions. Different interaction patterns, supported by high-quality evidence, included eight proteins intertwined in the “acute phase” (CRP, F2, SERPINA1 and IL1A) and/or in the “fibrinogen complex” (CRP, F2, PLAT, THBS1, VWF and FGB) significantly enriched terms. In a wide group of candidate genes, this approach highlighted six low-frequency variants (CRP Leu61Pro, F2 Asn514Lys, SERPINA1 Arg63Cys, THBS1 Asp901Glu, VWF Arg1399His and PLAT Arg164Trp), five of which were top ranked for predicted deleteriousness, which in different combinations may contribute to disease susceptibility in members of this family.
- 7 September 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (18) , 13809
Open AccessWhole-Exome Sequencing in a Family with an Unexplained Tendency for Venous Thromboembolism: Multicomponent Prediction of Low-Frequency Variant Deleteriousness and of Individual Protein Interaction
Whole-exome sequencing (WES) in families with an unexplained tendency for venous thromboembolism (VTE) may favor detection of low-frequency variants in genes with known contribution to hemostasis or associated with VTE-related phenotypes. WES analysis in six family members, three of whom affected by documented VTE, filtered for MAF < 0.04 in 192 candidate genes, revealed 22 heterozygous (16 missense and six synonymous) variants in patients. Functional prediction by multi-component bioinformatics tools, implemented by a database/literature search, including ClinVar annotation and QTL analysis, prioritized 12 missense variants, three of which (CRP Leu61Pro, F2 Asn514Lys and NQO1 Arg139Trp) were present in all patients, and the frequent functional variants FGB Arg478Lys and IL1A Ala114Ser. Combinations of prioritized variants in each patient were used to infer functional protein interactions. Different interaction patterns, supported by high-quality evidence, included eight proteins intertwined in the “acute phase” (CRP, F2, SERPINA1 and IL1A) and/or in the “fibrinogen complex” (CRP, F2, PLAT, THBS1, VWF and FGB) significantly enriched terms. In a wide group of candidate genes, this approach highlighted six low-frequency variants (CRP Leu61Pro, F2 Asn514Lys, SERPINA1 Arg63Cys, THBS1 Asp901Glu, VWF Arg1399His and PLAT Arg164Trp), five of which were top ranked for predicted deleteriousness, which in different combinations may contribute to disease susceptibility in members of this family.
- Open Access
- 18 January 2023
- Published by Elsevier in Thrombosis Research
- Vol. 223, 24-33
Head-to-head comparison of four COVID-19 vaccines on platelet activation, coagulation and inflammation. The TREASURE study
- 18 January 2023
- Published by Elsevier in Thrombosis Research
- Vol. 223, 24-33
Open AccessHead-to-head comparison of four COVID-19 vaccines on platelet activation, coagulation and inflammation. The TREASURE study
- 31 October 2021
- Published by Oxford University Press (OUP) in European Journal of Cardio-Thoracic Surgery
- Vol. 62 (1)
Bleeding in patients with continuous-flow left ventricular assist devices: acquired von Willebrand disease or antithrombotics?
OBJECTIVES: To evaluate the competing pro-haemorrhagic contribution of acquired von Willebrand (vW) disease and antithrombotic therapy in patients implanted with continuous-flow left ventricular assist devices (LVADs). METHODS: We compared the extent of vW factor (vWf) degradation [vWf antigen (vWf:Ag)] and a decrease of functional activity of large vWf multimers [vWf collagen binding (vWf:CB)] in LVAD patients who did and did not suffer from bleeding. Data were measured pre-implant, at short-term (t1: 12 months) follow-up. The occurrence of primary bleeding events, as well as bleeding recurrence, was correlated with patient-specific vWf profile and antithrombotic regimen. Indeed, patients were discharged on warfarin (international normalized ratio: 2–2.5) and aspirin, with the latter withhold after a first bleeding episode. RESULTS: Fifty-three patients were enrolled. The median follow-up was 324 (226–468) days. We recorded 25 primary bleeding events (47% of patients). All primary events occurred in patients on warfarin and aspirin. Both vWf:Ag and vWf:CB decreased significantly post-implant (P = 0.0003 and P < 0.0001), and patients showing pathological vWf:CB/vWf:Ag ratio (<0.7) increased progressively over the time of support (pre-implant = 26%, t1 = 58%, t2 = 74%; P < 0.0001). Of note, activity of large vWf multimers of bleeders was significantly lower at t2 with respect to non-bleeders (vWf:CB: 61 (36–115) vs 100 (68–121), P = 0.04; vWf:CB/vWf:Ag ratio: 0.36 (0.26–0.61) vs 0.58 (0.33–0.96), P = 0.04). Despite these marked differences in the vWf profile, following aspirin discontinuation only 3 patients had bleeding recurrence. CONCLUSIONS: Aspirin contributes significantly to haemorrhagic events in the background of acquired vW disease; its discontinuation significantly reduces bleeding recurrence. Clinical trial registration: https://clinicaltrials.gov/ct2/show/NCT03255928; ClinicalTrials.gov Identifier: NCT03255928.
- 31 October 2021
- Published by Oxford University Press (OUP) in European Journal of Cardio-Thoracic Surgery
- Vol. 62 (1)
Bleeding in patients with continuous-flow left ventricular assist devices: acquired von Willebrand disease or antithrombotics?
OBJECTIVES: To evaluate the competing pro-haemorrhagic contribution of acquired von Willebrand (vW) disease and antithrombotic therapy in patients implanted with continuous-flow left ventricular assist devices (LVADs). METHODS: We compared the extent of vW factor (vWf) degradation [vWf antigen (vWf:Ag)] and a decrease of functional activity of large vWf multimers [vWf collagen binding (vWf:CB)] in LVAD patients who did and did not suffer from bleeding. Data were measured pre-implant, at short-term (t1: 12 months) follow-up. The occurrence of primary bleeding events, as well as bleeding recurrence, was correlated with patient-specific vWf profile and antithrombotic regimen. Indeed, patients were discharged on warfarin (international normalized ratio: 2–2.5) and aspirin, with the latter withhold after a first bleeding episode. RESULTS: Fifty-three patients were enrolled. The median follow-up was 324 (226–468) days. We recorded 25 primary bleeding events (47% of patients). All primary events occurred in patients on warfarin and aspirin. Both vWf:Ag and vWf:CB decreased significantly post-implant (P = 0.0003 and P < 0.0001), and patients showing pathological vWf:CB/vWf:Ag ratio (<0.7) increased progressively over the time of support (pre-implant = 26%, t1 = 58%, t2 = 74%; P < 0.0001). Of note, activity of large vWf multimers of bleeders was significantly lower at t2 with respect to non-bleeders (vWf:CB: 61 (36–115) vs 100 (68–121), P = 0.04; vWf:CB/vWf:Ag ratio: 0.36 (0.26–0.61) vs 0.58 (0.33–0.96), P = 0.04). Despite these marked differences in the vWf profile, following aspirin discontinuation only 3 patients had bleeding recurrence. CONCLUSIONS: Aspirin contributes significantly to haemorrhagic events in the background of acquired vW disease; its discontinuation significantly reduces bleeding recurrence. Clinical trial registration: https://clinicaltrials.gov/ct2/show/NCT03255928; ClinicalTrials.gov Identifier: NCT03255928.
- Open Access
- 1 September 2019
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 144 (3) , 825-838
Lentiviral gene therapy corrects platelet phenotype and function in patients with Wiskott-Aldrich syndrome
- 1 September 2019
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 144 (3) , 825-838
Open AccessLentiviral gene therapy corrects platelet phenotype and function in patients with Wiskott-Aldrich syndrome
- 17 April 2019
- Published by Wiley in Haemophilia
- Vol. 25 (4) , 685-692
Missense changes in the catalytic domain of coagulation factor X account for minimal function preventing a perinatal lethal condition
Introduction: Inherited deficiencies in the coagulation pathway provide diversified models to investigate the molecular bases of perinatal lethality associated with null‐like variants. Differently from X‐linked haemophilias, homozygous/doubly heterozygous null variants in the rare autosomally inherited deficiency of factor X (FX) might be incompatible with perinatal survival.Aim: To provide experimental evidence about the null/close‐to‐null FX function.Methods: The residual secreted (ELISA) and functional (thrombin generation assays) protein levels associated with the novel nonsense (c.1382G>A; p.Trp461Ter) and missense (c.752T>C; p.Leu251Pro) variants, found in the proposita with life‐threatening symptoms at birth, were characterized through recombinant (r)FX expression.Results: The rFX‐461Ter showed very low secretion and undetectable function. Expression and function of the predicted readthrough‐deriving missense variants (rFX‐461Tyr, rFX‐461Gln) were also severely impaired. These unfavourable features, due to nucleotide and protein sequence constraints, precluded functional readthrough over the 461 stop codon. Differently, the poorly secreted rFX‐251Pro variant displayed residual function that was characterized by anti‐TFPI aptamer‐based amplification or selective inhibition of activated FX function by fondaparinux in plasma and found to be reduced by approximately three orders of magnitude. Similarly to the rFX‐251Pro, a group of catalytic domain missense variants cause poorly secreted molecules with modest function in FX‐deficient patients with life‐threatening symptoms.Conclusions: Our data, contributing to the knowledge of the very severe FX deficiency forms, support life‐saving requirement of trace FX function, clearly exemplified by the dysfunctional but not completely inactive rFX‐251Pro variant that, albeit with severely reduced function, is compatible with a residual activity ensuring minimal haemostasis and permitting perinatal survival.
- 17 April 2019
- Published by Wiley in Haemophilia
- Vol. 25 (4) , 685-692
Missense changes in the catalytic domain of coagulation factor X account for minimal function preventing a perinatal lethal condition
Introduction: Inherited deficiencies in the coagulation pathway provide diversified models to investigate the molecular bases of perinatal lethality associated with null‐like variants. Differently from X‐linked haemophilias, homozygous/doubly heterozygous null variants in the rare autosomally inherited deficiency of factor X (FX) might be incompatible with perinatal survival.Aim: To provide experimental evidence about the null/close‐to‐null FX function.Methods: The residual secreted (ELISA) and functional (thrombin generation assays) protein levels associated with the novel nonsense (c.1382G>A; p.Trp461Ter) and missense (c.752T>C; p.Leu251Pro) variants, found in the proposita with life‐threatening symptoms at birth, were characterized through recombinant (r)FX expression.Results: The rFX‐461Ter showed very low secretion and undetectable function. Expression and function of the predicted readthrough‐deriving missense variants (rFX‐461Tyr, rFX‐461Gln) were also severely impaired. These unfavourable features, due to nucleotide and protein sequence constraints, precluded functional readthrough over the 461 stop codon. Differently, the poorly secreted rFX‐251Pro variant displayed residual function that was characterized by anti‐TFPI aptamer‐based amplification or selective inhibition of activated FX function by fondaparinux in plasma and found to be reduced by approximately three orders of magnitude. Similarly to the rFX‐251Pro, a group of catalytic domain missense variants cause poorly secreted molecules with modest function in FX‐deficient patients with life‐threatening symptoms.Conclusions: Our data, contributing to the knowledge of the very severe FX deficiency forms, support life‐saving requirement of trace FX function, clearly exemplified by the dysfunctional but not completely inactive rFX‐251Pro variant that, albeit with severely reduced function, is compatible with a residual activity ensuring minimal haemostasis and permitting perinatal survival.
- 1 January 2019
- Published by Wolters Kluwer Health in Blood Coagulation & Fibrinolysis
- Vol. 30 (1) , 52-53
May restricted specificity of commercially available plasmin inhibitor activity assays affect correct diagnosis of antiplasmin deficiency?
- 1 January 2019
- Published by Wolters Kluwer Health in Blood Coagulation & Fibrinolysis
- Vol. 30 (1) , 52-53
May restricted specificity of commercially available plasmin inhibitor activity assays affect correct diagnosis of antiplasmin deficiency?
- 1 January 2019
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 27, 403-405
Acquired haemophilia A as a secondary autoimmune disease after alemtuzumab treatment in multiple sclerosis: A case report
- 1 January 2019
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 27, 403-405
Acquired haemophilia A as a secondary autoimmune disease after alemtuzumab treatment in multiple sclerosis: A case report
- 25 July 2018
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 10 (451)
Platelet microparticles sustain autophagy-associated activation of neutrophils in systemic sclerosis
Platelet microparticles from patients with systemic sclerosis prompt endothelial cell activation, neutrophil recruitment, and lung fibrosis.
- 25 July 2018
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 10 (451)
Platelet microparticles sustain autophagy-associated activation of neutrophils in systemic sclerosis
Platelet microparticles from patients with systemic sclerosis prompt endothelial cell activation, neutrophil recruitment, and lung fibrosis.
- 1 February 2018
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 105 (2) , E47-E49
Which Antiplatelet Therapy in Patients With Left Ventricular Assist Device and Aspirin Allergy?
- 1 February 2018
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 105 (2) , E47-E49
Which Antiplatelet Therapy in Patients With Left Ventricular Assist Device and Aspirin Allergy?